Cambridge Investment Research Advisors, Inc. Neurocrine Biosciences Inc Transaction History
Cambridge Investment Research Advisors, Inc.
- $26 Billion
- Q1 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 2,472 shares of NBIX stock, worth $351,617. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,472Holding current value
$351,617% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
628Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.96 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.41 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$568 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$326 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$320 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...